Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal decision profile

Journal of Hematology & Oncology

Medicine · Immunology and Microbiology
BioMed CentralUnited KingdomeISSN 1756-8722
Checking system sharing availability.Visit homepage
Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
31.9

Journal Metrics Score 2026 · 2021–2024 window citedness 33.23.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
80 daysmedian

Middle 50%: 58–106 days

99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$4,390

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
31.92026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#127 / 665LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
70.1%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
5.60MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
80 daysIQR 58–106 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
160 / yr2021–2024 AVG
Field-normalized top 10% share70.1%

448 of 639 works · same type, year & subfield

Field-normalized top 1% share29.1%

186 works · same type, year & subfield

Median FWCI5.60×

Above field-year expectation

Source output rank#127

of 665 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 5.60, so its typical recent paper runs about 460% above its field benchmark.

What does Top 10% Share mean?

70.1% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

1382016
1752017
1432018
1452019
1742020
2062021
1782022
1232023
1322024
1182025

Recent work-type mix

639 OpenAlex works · 2021–2024

Article92.3%
Erratum5.8%
Retraction0.9%
Conference abstract0.5%
Review0.5%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works
NeoplasmsLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic AgentsReceptors, Chimeric AntigenLung NeoplasmsImmunotherapy, AdoptiveTumor Microenvironment

Leading OpenAlex topics

2021–2024 works
CAR-T cell therapy research71
Acute Myeloid Leukemia Research44
Cancer Immunotherapy and Biomarkers28
Multiple Myeloma Research and Treatments20
RNA modifications and cancer20
Lymphoma Diagnosis and Treatment19
Cancer-related molecular mechanisms research18
Immune cells in cancer17
SARS-CoV-2 and COVID-19 Research15
Chronic Lymphocytic Leukemia Research14
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 639 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Recommended alternatives

Candidates share the leading OpenAlex topic, then subfield or field when needed, and are ranked by current Journal Metrics Score.

OpenAlex topic-neighbor model · Preview
Experimental Hematology & OncologyTopic-neighbor alternative12.9Metrics Score98dIQR 73–157dSubmission → acceptance$$Cost*Molecular Therapy OncologyTopic-neighbor alternative2.6Metrics Score—Submission → acceptance$—Cost*Cancer JournalTopic-neighbor alternative1.9Metrics Score—Submission → acceptance$—Cost*Cancer CellTopic-neighbor alternative32.1Metrics Score200dIQR 29–320dSubmission → acceptance$$$Cost*Journal of the National Cancer CenterTopic-neighbor alternative18.5Metrics Score—Submission → acceptance$$Cost*Nature CancerTopic-neighbor alternative16.2Metrics Score331dIQR 235–519dSubmission → acceptance$$$Cost*

More alternative journals

Biomarker ResearchInternational Journal of OncologyCancer and Metastasis ReviewsCell Reports MedicineSeminars in Cancer BiologyMedcomm

* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
OncologyQ1
HematologyQ1
Pathology and Forensic MedicineQ1

Considering submitting to Journal of Hematology & Oncology?

Use your manuscript title to find AI-ranked journals with related recent work, fit reasons, risks, and submission strategy.

Match my manuscript →
Q1
Subfield Quartile
B1
CAS Block

Ranking and source check

#4
of 853 Oncology field journals
#4
among Q1 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

View all Oncology journals →View Q1 Oncology journals →

Journal Details

OpenAlex Works
2,203
H-Index
231
Fully Open Access
Yes
Recent OA Works
2,193
Subject Areas
OncologyHematologyPathology and Forensic MedicineOncology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

Related Guides

Field Rankings
Best Oncology Journals: Journal Metrics Scores and Cancer Research Guide
12 min read
Field Rankings
Archived Medical Journal Selection Guide
14 min read
Publishing Guide
How to Choose the Right Journal for Your Research Paper
15 min read
Publishing Guide
Journal Selection Criteria: Essential Factors for Choosing the Right Publication Venue
20 min read
Back to Search